Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PEPD | P12955 | 2/20 | 0.40 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275226 | 1.00 | POLB (0.49) | POLBCYP3A4CYP2D6FKBP1ALTA4H | |
| SCHEMBL3568144 | 1.00 | POLB (0.49) | POLBCYP3A4CYP2D6FKBP1ALTA4H | |
| SCHEMBL2616299 | 0.94 | FKBP1A (0.49) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL15316989 | 0.94 | FKBP1A (0.49) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL12886363 | 0.94 | FKBP1A (0.49) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29447337 | 0.92 | FKBP1A (0.48) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL2772253 | 0.87 | — | — | |
| SCHEMBL19165735 | 0.86 | POLB (0.52) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL19165790 | 0.86 | POLB (0.52) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL19166211 | 0.86 | POLB (0.52) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-24 | — | — | US | claimed |
| EP-4399209-A1 | NEW QUINOLINE DERIVATIVES | Elanco Animal Health GmbH (DE) | 2024-07-17 | — | — | EP | claimed |
| WO-2023036821-A1 | NEW QUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-03-16 | — | — | WO | claimed |
| EP-4148052-A1 | NEW QUINOLINE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| CN-114409584-A | Preparation method of 1-methylpyrrolidine-2-formaldehyde | 重庆医药高等专科学校 | 2022-04-29 | — | — | CN | claimed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | claimed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | claimed |
| JP-2003502405-A | — | — | 2003-01-21 | — | — | JP | claimed |
| EP-1194410-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | claimed |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-24 | — | — | US | disclosed |
| EP-4399209-A1 | NEW QUINOLINE DERIVATIVES | Elanco Animal Health GmbH (DE) | 2024-07-17 | — | — | EP | disclosed |
| CN-115093355-B | Preparation method of pyrrole ester compound | 河南农业大学 | 2024-06-04 | — | — | CN | disclosed |
| EP-4310093-A1 | AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS, COMPRISING SAME | Prazertherapeutics Inc. (KR) | 2024-01-24 | — | — | EP | disclosed |
| CN-112074507-B | Compounds as Antibiotics | 山东亨利医药科技有限责任公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-0588917-A4 | — | — | 1994-04-13 | — | — | EP | disclosed |
| EP-0588917-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-03-30 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| WO-1992021339-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0253785-B1 | EFFICIENT STEREOCONSERVATIVE SYNTHESES OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THEREIN | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | POLB 4499/4885CYP3A4 35/4885CYP2D6 410/4885 |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | RECQL, QTRT2, NQO2 | POLB 2245/4885CYP3A4 143/4885CYP2D6 144/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | POLB 4392/4885CYP3A4 33/4885CYP2D6 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.